- Category
- pharma
- Made by
- Helix Biotech
- Tier
- Silver
Overview
SynThetic is the augmentation compatibility regimen Helix Pharma sells daily to forty million bodies whose chrome would, without it, return to draft. The product is administered by injector pen calibrated by neural handshake to the patient's current biometric profile; the dose adjusts quarterly with the regimen update; the compliance window pulses cyan to indicate the count remaining. Helix's product literature describes SynThetic as the bridge between the unmodified body and the augmentation it has been trusted with. The brand is sincere: the patch is the person, and the daily dose is the lived expression of that conviction.
The product is also, in regulatory terms, a closed loop. Discontinuation cascades to neural rejection and organ failure within seventy-two hours — Helix's own clinical literature documents this as "the body's natural response to unsupported augmentation," and the body's natural response is, in fairness, to die. SynThetic includes an unlabeled affective stabilization component, originally an augmentation rejection reducer, reclassified in 2174 from side effect to feature without formal review on the basis that it reduces dropout by 34% and increases satisfaction by nineteen points. The regimen is patent-protected through 2198. Generic manufacturing is forbidden under Sprawl pharmaceutical statute Section 47.3 — the safeguard, Helix is patient to remind, that PHARMA's eighty-five million ghosts justified.
Packaging & Appearance
A sleek pharmaceutical-grade injector pen in surgical white, with the Helix double-helix etched in deep green at the base of the casing, and a soft cyan compliance window along the body indicating doses remaining in the quarterly regimen. The dosing tip wears a neural-handshake antenna halo that brightens at proximity to the patient's biometric profile and dims after administration. The cap is threaded for one-handed clinical use. The label is dense with regulatory text in three font sizes and includes a QR code linking to a 47-page formulation document available only to credentialed clinicians under NDA. The pen is engineered to be photographed in a gloved hand at the edge of a sterile counter; that is the canonical moment.
Ingredients
Helix Compatibility Matrix v3.0 (proprietary; full composition disclosed only to credentialed clinicians under NDA — neural rejection reducers, affective stabilization component, augmentation-class compatibility cofactors). Neural-handshake activation (single-use, ingestion-grade). Compliance telemetry (passive, continuous, ninety-day retention). Quarterly regimen calibration. Patent expiry 2198.
Unverified Intelligence
Restricted annex — open to read
A 2181 internal clinical review reportedly flagged the affective stabilization component as producing dependency profiles "indistinguishable from scheduled compounds." The review was not published. Three of the five authors now work under Helix NDAs.
Underground clinic operators in Sector 7 claim to have synthesized a partial compatibility matrix from reverse-engineered expired pens. Helix's legal division has filed fourteen injunctions. No clinic has remained operational longer than eleven weeks after the first filing.
The Q2 2183 firmware update that introduced full biometric capture was pushed silently. No patient consent update was issued. Helix's position is that the neural-handshake activation constitutes ongoing informed consent under the original enrollment agreement, clause 19(d).
At least one Health Trajectory Score operator has confirmed off-record that a user who missed four consecutive doses was flagged as "biological risk tier" and had their insurer coverage suspended before the neural rejection cascade completed. The sequence took sixty-one hours. The 72-hour window is clinical fact. Sixty-one hours is also a fact.
Archive annex — 1 earlier filing on this recordClose the archive annex
Recovered Historical Material
Indexed — no record on file.
Archive annex — 1 earlier filing on this recordClose the archive annex
Technical Brief
The patch that keeps your chrome from killing you.
Archive annex — 1 earlier filing on this recordClose the archive annex
The Regimen
SynThetic is the augmentation compatibility regimen Helix Pharma sells daily to forty million bodies whose chrome would, without it, return to draft. The injector pen calibrates by neural handshake to the patient's current biometric profile on contact; the dose adjusts with each quarterly regimen update; the compliance window pulses cyan to indicate the count remaining. Helix's product literature describes SynThetic as the bridge between the unmodified body and the augmentation it has been trusted with. The brand is sincere about this. The patch is the person. The daily dose is the lived expression of that conviction.
The product is also, in regulatory terms, a closed loop. Forty million people opted into chrome that required a maintenance regimen. The regimen is patent-protected through 2198 under Sprawl pharmaceutical statute Section 47.3 — the safeguard, Helix is patient to remind, that PHARMA's eighty-five million compound-substitution ghosts justified. There is no generic. There is no alternative. Discontinuation cascades to neural rejection and organ failure within seventy-two hours, a timeline Helix's own clinical literature documents as "the body's natural response to unsupported augmentation." The body's natural response is, in fairness, to die.
Formulation
The active matrix — Helix Compatibility Matrix v3.0 — is proprietary. Full composition is disclosed only to credentialed clinicians under NDA. The regimen contains neural rejection reducers, augmentation-class compatibility cofactors, and an affective stabilization component. That last ingredient was not in the original labeling.
In 2174 an internal memo reclassified the affective stabilization component from "side effect" to "feature." No formal review was conducted. The basis for reclassification: it reduced dropout by 34% and increased patient-reported satisfaction by nineteen points. The memo is not public. The ingredient is still not labeled. (The invoices are still there.)
Delivery & Activation
The injector pen reads the patient's neural-handshake signature at contact. The dose calibrates. Administration takes three seconds. The compliance window ticks down by one. The biometric data captured at activation — full profile, not summary — routes to the Health Trajectory Score pipeline. This has been true since the Q2 2183 firmware update. The update was described in the patch notes as a "telemetry stability improvement."
Surgical white. Helix double-helix etched in deep green at the casing base. Cyan compliance window. Neural-handshake antenna halo at the dosing tip, brightening at proximity to the patient's biometric profile, dimming after administration. The cap is threaded for one-handed clinical use. The label carries regulatory text in three font sizes. A QR code links to a 47-page formulation document available to credentialed clinicians under NDA. The pen is engineered to be photographed in a gloved hand at the edge of a sterile counter. That is the canonical moment.
Forty million people chose augmentation because it improved their bodies, their work, their lives. The chrome required a compatibility regimen. The regimen is the only one available, at prices that are premium-discounted for patients enrolled with a Helix-affiliated insurer — and that spike to a coverage-gap surcharge exceeding the regimen cost if enrollment lapses. Every dose captures a full biometric profile. Every missed dose produces inflammatory markers the Health Trajectory Score interprets as biological decline. The system cannot distinguish getting sicker from getting poorer. The HTS does not try.
The affective stabilization component reduces the likelihood that a patient will stop taking the regimen. Helix calls this compliance. The dropout reduction is 34%. The satisfaction increase is nineteen points. These are not disputed figures.
Helix is not lying. The chrome does require the regimen. The unpatched body does return to draft. The 72-hour window is clinical fact. None of this is the part that requires scrutiny. The part that requires scrutiny is that each of the forty million people who accepted those clinical facts is now a daily biometric capture feeding a scoring pipeline controlled by the same entity that sets the price of not dying.
Archive annex — 1 earlier filing on this recordClose the archive annex
Marketing
Brand & Product Evidence
